Takeda Pharmaceutical (TAK) Income from Continuing Operations (2017 - 2026)

Takeda Pharmaceutical's Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 154675973.07 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 105.51% year-over-year to 154675973.07; the TTM figure through Mar 2026 stood at 11329629639.3 (down 10.61% YoY), while the FY2026 annual figure was 1275664180.2, up 79.69% from the prior year.
• Income from Continuing Operations was 154675973.07 for Q1 2026 at Takeda Pharmaceutical, down from 1371057036.19 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 7493939408.37 in Q3 2025 to a low of 154675973.07 in Q1 2026.
• Historically, Income from Continuing Operations has averaged 2171051827.84 across 5 years, with a median of 1557353005.98 in 2023.
• The sharpest annual moves came in 2023 and 2026: Income from Continuing Operations jumped 360.67% in 2023, then plunged 105.51% in 2026.
• A 5-year view of Income from Continuing Operations shows it stood at 673551561.9 in 2022, then jumped by 161.65% to 1762343122.5 in 2023, then retreated by 25.02% to 1321474924.64 in 2024, then advanced by 3.75% to 1371057036.19 in 2025, then tumbled by 111.28% to 154675973.07 in 2026.
• The last three Income from Continuing Operations figures came in at 154675973.07 (Q1 2026), 1371057036.19 (Q4 2025), and 7493939408.37 (Q3 2025), per Business Quant data.